Evidence map›Paper›PMID 32535213›Full record

ArticleEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences2020

In vitro release of hydrophobic drugs by oleogel rods with biocompatible gelators.

Russell Macoon, Mackenzie Robey, Anuj Chauhan

Open access · greenAbstract read
In one paragraph

Article in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Ophthalmic delivery of hydrophilic drugs through drug-loaded oleogels.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Russell MacoonDepartment of Chemical Engineering; University of Florida; Gainesville, FL 32611.
Mackenzie RobeyDepartment of Chemical Engineering; University of Florida; Gainesville, FL 32611.
Anuj ChauhanDepartment of Chemical Engineering; Colorado School of Mines;1613 Illinois Street Alderson Hall Rm 251 Golden, Golden, CO 80401, United States. Electronic address: chauhan@mines.edu.
University of Florida · USColorado School of Mines · US

Funding

RESEARCH TRAINING IN VISION SCIENCET32EY007132 · NEI · UNIVERSITY OF FLORIDA · PI W CLAY SMITH · 1991 to 2026
$3.8M
NEI NIH HHS T32 EY007132
6 · The paper itself

Abstract

purposeCurrently, invasive monthly intravitreal injections through the eyeball are required to deliver retinal drugs. Injections of oleogels into the vitreous have the potential for extended release of both hydrophobic and hydrophilic drugs for extended durations which could decrease the frequency of injections. The type of gelator used is critical because it may impact drug release and also the biocompatibility of the device.

methodsOleogels containing soybean oil as the liquid component and beeswax, a combination of β-sitosterol and lecithin, sorbitan monostearate, sunflower wax, ethyl cellulose, or a combination of γ-oryzanol with β-sitosterol as the gelator were loaded with the drugs dexamethasone, cyclosporine, triamcinolone, vancomycin above the solubility limit and expunged from a syringe to create cylindrical rods for extended drug delivery. Images of the devices were taken to observe the dispersal of drug particles. In vitro drug release in buffer solutions was measured and effective drug diffusivity was determined from a fitted model. Effect of molecular weight and drug binding to the gelator on diffusivity was explored.

resultsAt loading above the solubility limit, the oleogel formulation contains drug particles that act as distributed depots resulting in extended release. The oleogels prepared with different gelators presented a wide range of drug release profiles. The release durations for 10% loading dexamethasone are 35 days for the β-sitosterol/lecithin gel and 135 days for the sorbitan monostearate gel. The γ-oryzanol/β-sitosterol gels released 81% after 135 days and the beeswax and sunflower wax gels released about 78% and 79% of the loaded dexamethasone after 30 days, respectively. In ethyl cellulose gels, the release duration of 28% cyclosporine was 13 days, 28% loaded dexamethasone released 66% after 125 days, 28% triamcinolone released 46% after 108 days, and vancomycin released 80% after 21 days. The solubility limit of the drug in the oleogel was increased in presence of gelator suggesting significant drug binding to the gelator. The effective diffusivity decreased with drug binding likely because the bound drug does not diffuse. The model based on accounting for drug particle depots fit the release data. Dissolution of the particles results in void formation that increases tortosity impacting effective diffusivity.

conclusionsOleogel based rods can provide extended release of many hydrophobic drugs. Solubility of drugs in the gels are affected by gelator type, which suggests some interaction between the drug and the gelling agent. Drug dissolution, diffusion, binding as well as tortuosity due to the formation of voids must be considered to model drug release. HYPOTHESIS: Currently, invasive monthly intravitreal injections through the eyeball are required to deliver retinal drugs. Consequently, oleogels have been explored as an extended release ocular implant for delivery of drug to the retina. The gelator component in these gels is ethyl cellulose, a polysaccharide that is not readily degradable in the eye. Comparing various biocompatible gelator molecules' ability to form drug incorporated oleogel formulations and their effect on drug release profiles could provide significant insight into development of oleogel devices. EXPERIMENTS: Oleogels containing soybean oil as the liquid component and beeswax, a combination of β-sitosterol and lecithin, sorbitan monostearate, sunflower wax, ethyl cellulose, or a combination of γ-oryzanol with β-sitosterol as the gelator were loaded with the drugs dexamethasone, cyclosporine, triamcinolone, vancomycin above the solubility limit and expunged from a syringe to create cylindrical rods for extended drug delivery. Images of the devices were taken to observe the dispersal of drug particles. In vitro drug release in buffer solutions was measured and effective drug diffusivity was determined from a fitted model.

findingsAt sufficient loading concentrations, drug particles are suspended in the gel and slowly release. The oleogels prepared with different gelators presented a wide range of drug release profiles. The release durations for 10% loading dexamethasone are 35 days for the β-sitosterol/lecithin gel and 135 days for the sorbitan monostearate gel. The γ-oryzanol/β-sitosterol gels released 81% after 135 days and the beeswax and sunflower wax gels released about 78% and 79% of the loaded dexamethasone after 30 days, respectively. In ethyl cellulose gels, the release duration of 28% cyclosporine was 13 days, 28% loaded dexamethasone released 66% after 125 days, 28% triamcinolone released 46% after 108 days, and vancomycin released 80% after 21 days. Solubility of drugs in the gels are affected by gelator type, which suggests some interaction between the drug and the gelling agent. Drug dissolution, diffusion, as well as tortuosity due to the formation of voids must be considered to model drug release.

Indexed as

LecithinsOrganic ChemicalsGelsHydrophobic and Hydrophilic InteractionsSolubilityGelsLecithinsoleogelsOrganic Chemicals

Identifiers

PMID32535213
PMCPMC8991997
OpenAlexW3035328663

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.